[{"data": {"name": "FDA should stand firm on stem-cell treatments", "@type": "ScholarlyArticle", "genre": "journal-article", "license": "cc-by", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "http://www.nature.com:80/polopoly_fs/1.20208!/menu/main/topColumns/topLeftColumn/pdf/535007b.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Springer Science and Business Media LLC", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1038/535007b", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCYLFiiypwtZW-CT5mexB35hBnN-CD6AzYq7GvKxM-CRXDsGLqqcT42", "propertyID": "ISCC"}], "datePublished": "2016-07-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]